Compare MRBK & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRBK | SGHT |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.3M | 235.0M |
| IPO Year | 2018 | 2021 |
| Metric | MRBK | SGHT |
|---|---|---|
| Price | $17.56 | $4.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $20.75 | $9.08 |
| AVG Volume (30 Days) | 122.6K | ★ 323.6K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | ★ 30.34 | 28.16 |
| EPS | ★ 0.17 | N/A |
| Revenue | $6,316,000.00 | ★ $77,363,000.00 |
| Revenue This Year | $25.40 | $11.67 |
| Revenue Next Year | $8.15 | $10.39 |
| P/E Ratio | $103.26 | ★ N/A |
| Revenue Growth | ★ 10.13 | N/A |
| 52 Week Low | $11.17 | $3.11 |
| 52 Week High | $21.59 | $9.24 |
| Indicator | MRBK | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 35.41 | 58.69 |
| Support Level | $17.05 | $4.86 |
| Resistance Level | $18.13 | $5.25 |
| Average True Range (ATR) | 0.85 | 0.34 |
| MACD | -0.15 | 0.09 |
| Stochastic Oscillator | 10.03 | 56.71 |
Meridian Corp is a bank holding company based in the United States. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal and business lending and deposit services. It operates in three reportable segments, including Bank, Wealth, and Mortgage. Meridian generates maximum revenue from the Bank segment, which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans. Geographically, it operates in Pennsylvania, New Jersey, and Delaware, as well as in the Central Maryland market and southwest Florida, U.S.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.